Q2 EPS Estimate for Oncobiologics Decreased by Analyst

Oncobiologics, Inc. (NASDAQ:OTLK) – Research analysts at Brookline Capital Acquisition decreased their Q2 2026 earnings estimates for Oncobiologics in a research report issued on Tuesday, February 17th. Brookline Capital Acquisition analyst K. Dolliver now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their prior forecast of ($0.16). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Capital Acquisition also issued estimates for Oncobiologics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.79) EPS and FY2027 earnings at ($0.20) EPS.

Oncobiologics (NASDAQ:OTLK) last released its earnings results on Tuesday, February 17th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The company had revenue of ($1.21) million during the quarter, compared to analysts’ expectations of $3.14 million.

A number of other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. HC Wainwright reissued a “neutral” rating on shares of Oncobiologics in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. Chardan Capital restated a “neutral” rating on shares of Oncobiologics in a research report on Wednesday. Finally, Ascendiant Capital Markets raised their price target on Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.50.

Oncobiologics Trading Up 6.1%

Shares of OTLK opened at $0.43 on Friday. The firm has a market cap of $36.10 million, a P/E ratio of -0.17 and a beta of 0.10. Oncobiologics has a 12 month low of $0.38 and a 12 month high of $3.39. The stock’s 50 day moving average is $0.93 and its two-hundred day moving average is $1.32.

Hedge Funds Weigh In On Oncobiologics

Several hedge funds and other institutional investors have recently made changes to their positions in OTLK. Goldman Sachs Group Inc. boosted its position in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares during the period. AQR Capital Management LLC increased its stake in Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

More Oncobiologics News

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital raised its Q4 2026 EPS estimate to ($0.18) from ($0.22), a modest improvement for that quarter which could be seen as a short-term positive for near-term expectations.
• Neutral Sentiment: Chardan Capital reiterated a “Neutral” rating on Oncobiologics, signaling no change in stance from that shop. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating even as it updated earnings models — the reaffirmation removes near-term rating-driven upside but keeps analyst coverage steady. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: A GlobeNewswire release circulating under the OTLK ticker concerns Outlook Therapeutics’ distribution deal in Switzerland — this appears to reference a different company using the same ticker string and may create market confusion; investors should confirm company identity before acting. Outlook Therapeutics Expands European Footprint (GlobeNewswire)
• Negative Sentiment: HC Wainwright trimmed multiple EPS forecasts: Q4 2026 to ($0.05) (from $0.04 previously), FY2026 to ($0.42) (from $0.28) and FY2027 to ($0.21) (from $0.19). These larger-than-expected cuts weigh on forward expectations and valuation.
• Negative Sentiment: Brookline Capital lowered several near-term and FY2026/2027 EPS estimates (e.g., FY2026 to ($0.79) from ($0.74); FY2027 to ($0.20) from ($0.19); quarter-level cuts to Q2/Q3 2026), signaling weaker anticipated performance and adding downside pressure.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.